<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metastatic uveal melanoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metastatic uveal melanoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metastatic uveal melanoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard D Carvajal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J William Harbour, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell S Berman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H508721688"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uveal melanoma is a rare malignancy that arises from melanocytes within the uveal tract of the eye, which includes the iris, ciliary body, and choroid  (<a class="graphic graphic_figure graphicRef59910" href="/d/graphic/59910.html" rel="external">figure 1</a>). Uveal melanoma comprises approximately 85 percent of all ocular melanomas, with the remainder arising mostly from the conjunctiva (5 percent) or other sites (10 percent) [<a href="#rid1">1,2</a>].</p><p>The clinical presentation, diagnosis, and management of metastatic uveal melanoma are discussed here. The molecular biology of uveal melanoma and clinical presentation, diagnosis, and initial management of uveal and conjunctival melanomas are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Uveal melanomas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas"</a>.)</p><p></p><p class="headingAnchor" id="H2446640153"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H359172928"><span class="h2">Timing of metastases</span><span class="headingEndMark"> — </span>Most patients develop metastatic uveal melanoma within five to seven years of treatment to the primary eye tumor, with a median time of approximately three years [<a href="#rid3">3</a>]. Metastases can also appear after a decade or longer [<a href="#rid4">4-6</a>]. Despite effective treatment of the primary site, the risk of distant metastasis among patients with uveal melanoma is up to 50 percent (depending on the genetic subtype [<a href="#rid4">4,7</a>]). (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p>Patients who present with a primary uveal melanoma and synchronous distant metastases are rare (less than four percent of all patients diagnosed with uveal melanoma) [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Staging of distant (extraocular) disease'</a>.)</p><p class="headingAnchor" id="H1711609819"><span class="h2">Sites of disease</span><span class="headingEndMark"> — </span>The most common sites of metastases from uveal melanoma include [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Liver (93 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Lung (24 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Bone (16 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Skin/subcutaneous tissue (11 percent).</p><p class="bulletIndent1"><span class="glyph">●</span>Lymph node and brain metastasis (5 to 6 percent) are rare [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H1906028502"><span class="h2">Clinical symptoms</span><span class="headingEndMark"> — </span>A majority of patients with metastatic uveal melanoma are asymptomatic at diagnosis since most cases are incidentally diagnosed during routine imaging surveillance. Patients with more indolent tumors, such as those harboring a <em>SF3B1</em> mutation, may also present without symptoms. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p>Patients with significant disease burden typically develop symptomatic metastases. These patients may present with constitutional symptoms such as fatigue, weight loss, and anorexia. The presence of other symptoms can indicate disease location, such as abdominal pain, swelling, fullness, or back pain for those with liver metastases; chest pain or shortness of breath for those with lung metastases; and bone pain or pathologic fractures for those with bony metastases [<a href="#rid3">3</a>]. Although central nervous system (CNS) metastases are generally rare, approximately six percent of patients with metastatic uveal melanoma develop neurologic symptoms, including headache, weakness, sensory loss, and confusion [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/7621.html" rel="external">"Staging work-up and surveillance of cutaneous melanoma", section on 'Symptoms of recurrence or metastatic disease'</a>.)</p><p class="headingAnchor" id="H4266553891"><span class="h2">Physical exam</span><span class="headingEndMark"> — </span>Patients with limited tumor burden may have normal physical exam findings. Painless skin or subcutaneous nodules may be present. Unlike cutaneous melanoma, regional lymphadenopathy is rare. (See  <a class="medical medical_review" href="/d/html/7618.html" rel="external">"Tumor, node, metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma", section on 'Regional involvement'</a>.)</p><p>Patients with high tumor burden and/or rapidly progressive disease involving the liver may demonstrate hepatomegaly, jaundice, or other stigmata of liver disease. (See  <a class="medical medical_review" href="/d/html/89223.html" rel="external">"Overview of the evaluation of hepatomegaly in adults", section on 'Physical examination'</a>.)</p><p class="headingAnchor" id="H2172823703"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The diagnosis of metastatic uveal melanoma should be suspected in patients with a known history of primary uveal melanoma and systemic metastases (such as predominant disease burden in the liver) diagnosed either on physical exam or imaging studies. Patients with indolent disease may be asymptomatic and are more likely to be diagnosed during routine posttreatment imaging surveillance. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p>Patients with <em>de novo</em> metastatic melanoma (especially those with hepatic metastases) and an unknown primary site should be referred to ophthalmology to assess for a primary lesion in the eye [<a href="#rid3">3</a>]. The diagnosis of a primary uveal melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Diagnosis of the primary tumor'</a>.)</p><p class="headingAnchor" id="H3329693882"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>For patients with suspected metastatic uveal melanoma, we obtain a complete blood count with differential, complete metabolic panel (including liver function testing, alkaline phosphatase, and total bilirubin), and lactate dehydrogenase.</p><p class="headingAnchor" id="H385069599"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>For patients with suspected metastatic uveal melanoma, we obtain imaging studies as an initial diagnostic step to assess clinical symptoms, disease extent, and as a baseline to assess treatment response. Imaging studies are also necessary to determine a metastatic site for tissue sampling. (See <a class="local">'Diagnostic biopsy'</a> below.)</p><p>We obtain magnetic resonance imaging (MRI) of the liver with <a class="drug drug_general" data-topicid="9085" href="/d/drug information/9085.html" rel="external">gadoxetate</a> (Eovist) contrast to assess for hepatic metastases. We also obtain contrast-enhanced computed tomography (CT) of the chest to assess for extrahepatic sites of disease. Patients may be offered the option of an MRI of the brain with contrast to assess for CNS metastases. We do not routinely obtain fludeoxyglucose (FDG)-positron emission tomography (PET)-CT as part of initial diagnostic imaging. Uveal melanoma is not consistently FDG-avid on PET-CT It is also difficult to visualize hepatic metastases due to normal liver uptake of FDG. (See  <a class="medical medical_review" href="/d/html/7625.html" rel="external">"Imaging studies in melanoma", section on 'Liver'</a>.)</p><p class="headingAnchor" id="H801268902"><span class="h2">Diagnostic biopsy</span><span class="headingEndMark"> — </span>The diagnosis of metastatic uveal melanoma is confirmed on biopsy and histopathologic evaluation of distant metastatic lesions, once metastatic lesions are detected on imaging studies. Further details on the histopathology of melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/4843.html" rel="external">"Pathologic characteristics of melanoma"</a>.)</p><p>Tissue can be obtained using fine needle aspiration (FNA) or core needle biopsy, depending upon the disease site. The metastatic tissue that is obtained for diagnosis (or archived tissue from the primary ocular tumor, if available) can also be assessed for molecular alterations, which can determine prognosis and guide management, including clinical trials. (See <a class="local">'Molecular analyses'</a> below and <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H2817983145"><span class="h2">Molecular analyses</span><span class="headingEndMark"> — </span>The molecular pathogenesis of uveal melanoma is distinct from that of cutaneous melanoma and other melanoma subtypes, including conjunctival melanoma. Uveal melanomas usually harbor specific initiating mutations in<em> GNAQ, GNA11</em>, or other members of the G protein alpha subunit signaling pathway, as well as secondary driver mutations with prognostic significance in genes such as <em>BAP1</em>, <em>SF3B1</em>, and <em>EIF1AX. </em>Further details of the specific molecular alterations found in uveal melanoma are discussed separately. (See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Uveal melanomas'</a>.)</p><p>Patients with metastatic uveal melanoma should have their tumors assessed using next generation sequencing (NGS) or gene expression profiling. While molecular alterations that are targetable for treatment are limited in uveal melanoma, some alterations may offer insights into prognosis as well as clinical trial options. A majority of patients with a known primary uveal melanoma may have already been assessed for these alterations, which are used to guide post-treatment surveillance. (See  <a class="medical medical_review" href="/d/html/7617.html" rel="external">"Initial management of uveal and conjunctival melanomas", section on 'Posttreatment systemic surveillance'</a>.)</p><p>In addition, we obtain a genotyping assay on whole blood for the presence of human leukocyte antigen (HLA)-A*02:01. Patients with this genotype are eligible for targeted therapy with <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a>. (See <a class="local">'Genotype assessment'</a> below and <a class="local">'HLA-A*02:01 positive'</a> below.)</p><p class="headingAnchor" id="H2598667818"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The American Joint Committee on Cancer AJCC and Union for International Cancer Control (UICC) tumor, node, metastasis (TNM) staging system is used to stage patients with uveal melanoma. Staging is also based on the primary location of ocular disease, such as the iris  (<a class="graphic graphic_table graphicRef110765" href="/d/graphic/110765.html" rel="external">table 1</a>) and choroidal and ciliary body  (<a class="graphic graphic_table graphicRef110766" href="/d/graphic/110766.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3922500161"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The optimal treatment approach for metastatic uveal melanoma is evolving. The choice of therapy is based upon clinical factors such as genotype assessment for HLA-A*02:01, tumor burden, rate of growth, and location, and the availability of clinical trials  (<a class="graphic graphic_algorithm graphicRef139783" href="/d/graphic/139783.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2631270166"><span class="h2">Genotype assessment</span><span class="headingEndMark"> — </span>Prior to initiating systemic therapy in all patients with metastatic uveal melanoma, we obtain a genotyping assay on whole blood for the presence of human leukocyte antigen (HLA)-A*02:01, which is seen in approximately 45 percent of individuals in the United States and Europe [<a href="#rid11">11</a>]. Patients who are HLA-A*02:01 positive are candidates for targeted therapies such as <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a>, whereas those who are negative are offered locoregional and/or other systemic therapies  (<a class="graphic graphic_algorithm graphicRef139783" href="/d/graphic/139783.html" rel="external">algorithm 1</a>). A companion diagnostic HLA sequencing system with regulatory approval is available [<a href="#rid12">12</a>]. (See <a class="local">'HLA-A*02:01 positive'</a> below.)</p><p class="headingAnchor" id="H1648316696"><span class="h2">HLA-A*02:01 positive</span></p><p class="headingAnchor" id="H3452033855"><span class="h3">Tebentafusp</span><span class="headingEndMark"> — </span>For patients with treatment-naïve metastatic uveal melanoma who are human leukocyte antigen (HLA)-A*02:01 positive, we suggest <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> rather than other systemic agents, as this approach improved overall survival (OS) over chemotherapy and checkpoint inhibitor immunotherapy in a phase III trial [<a href="#rid11">11</a>].</p><p>Patients who are ineligible for <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> (eg, due to systemic immunosuppression) or those with bulky or rapidly progressive disease may be treated using the same approach as those without the HLA-A*02:01 genotype. Although tebentafusp improves OS, including those whose best response was progressive disease, progression-free survival (PFS) and objective response rates are modest with this agent, and other therapies may offer more rapid disease control. (See <a class="local">'HLA-A*02:01 negative'</a> below.)</p><p><a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">Tebentafusp</a> is administered using a dose-escalation strategy of 20 mcg on day 1, 30 mcg on day 8, and 68 mcg on day 15 and weekly thereafter. Due to the risk of cytokine release syndrome (CRS), the first three doses of tebentafusp should be administered in a tertiary care inpatient setting with expertise in the management of CRS, where patients can be monitored during the infusion and for at least 16 hours after treatment completion. Patients who do not experience grade ≥2 hypotension that requires medical intervention during or after the third infusion can receive subsequent doses in an ambulatory infusion clinic, with monitoring for a minimum of 30 minutes following each infusion [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a>.)</p><p><a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">Tebentafusp</a> (IMCgp100), a first-in-class immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC), is comprised of a targeting end that constitutes a soluble affinity-enhanced HLA-A*02:01 restricted T cell receptor targeting glycoprotein 100, a uveal melanoma antigen, and an effector end targeting CD3  (<a class="graphic graphic_figure graphicRef135190" href="/d/graphic/135190.html" rel="external">figure 2</a>) [<a href="#rid11">11,14,15</a>]. Once tebentafusp binds the peptide-HLA complexes expressed on the cancer cells, it activates polyclonal T cells through CD3 to release cytokines and cytolytic mediators against those cells. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immune-mobilizing monoclonal TCRs against cancer'</a>.)</p><p>Based on initial phase I and II trial data [<a href="#rid16">16,17</a>], a phase III trial was conducted in 378 patients with positive HLA-A*02:01 and systemic treatment-naïve advanced uveal melanoma, with no prior liver-directed therapy (except surgery) and any level of LDH [<a href="#rid11">11</a>]. Other exclusion criteria included symptomatic central nervous system (CNS) metastases, autoimmune disease being treated with glucocorticoids, and active systemic immunosuppressive therapy. Patients were randomly assigned in a 2:1 ratio to <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> or investigator's choice of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, or <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>.</p><p>At a minimum follow-up of 36 months, compared with investigator's choice of therapy, <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> improved both OS (three-year OS 27 versus 18 percent; median OS 22 versus 17 months; hazard ratio [HR] 0.68, 95% CI 0.54-0.87) and PFS (six-month PFS 31 versus 19 percent; median 3.4 versus 2.9 months; HR 0.76, 95% CI 0.6-0.97) [<a href="#rid11">11,18</a>]. Tebentafusp also improved OS in patients whose best response was progressive disease (median 15 versus 7 months; HR 0.43, 95% CI 0.27-0.68). Objective responses were higher with tebentafusp (11 versus 5 percent), including one patient with a complete response. This disassociation between response rates and OS outcomes for tebentafusp is attributed to a different form to treatment response with this agent than has previously been seen with chemotherapy.</p><p>CRS occurred in 89 percent of patients receiving <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a>. However, most treatment-related toxicities decreased in frequency and severity after the first three to four doses. Grade ≥3 toxicities include rash (19 percent), pruritus (5 percent), pyrexia (5 percent), hypotension (4 percent), and fatigue (3 percent). No tebentafusp-related deaths were reported.</p><p>Based on these data, the US Food and Drug Administration (FDA) approved <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a> for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma [<a href="#rid13">13</a>]. Tebentafusp also is approved by the European Medicines Agency (EMA) for the treatment of metastatic uveal melanoma [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3463209995"><span class="h2">HLA-A*02:01 negative</span><span class="headingEndMark"> — </span>For patients with treatment-naïve metastatic uveal melanoma who are not HLA-A*02:01-positive or those with bulky or rapidly progressive disease, we offer enrollment in formal clinical trials whenever possible. </p><p>For those who decline or are not eligible for clinical trials, our initial treatment approach is based on disease location, patient characteristics, and treatment preferences. The optimal treatment approach is not established as randomized studies are limited in this rare disease.</p><p class="headingAnchor" id="H1530923716"><span class="h3">Liver-dominant disease</span></p><p class="headingAnchor" id="H2572762763"><span class="h4">Treatment approach</span><span class="headingEndMark"> — </span>For patients with liver-dominant disease, we suggest locoregional therapies rather than systemic therapy. However, initial systemic therapy is an appropriate alternative. Some patients may reasonably opt for this strategy, given the generally poor prognosis of metastatic uveal melanoma and limited randomized trials comparing locoregional and systemic therapies. (See <a class="local">'Prognosis'</a> below and <a class="local">'Significant extrahepatic disease'</a> below.)</p><p>After completion of locoregional therapy, patients with treated liver-dominant disease may be observed for disease progression with imaging studies every six to eight weeks<strong>. </strong>We reserve systemic therapy for patients with significant extra-hepatic disease or those who are ineligible for locoregional treatment. (See <a class="local">'Significant extrahepatic disease'</a> below.)</p><p>Most patients with both liver-dominant and limited extrahepatic disease may receive liver-directed therapy followed by systemic therapy. Systemic therapy can be initiated once liver-directed therapy has achieved some degree of hepatic disease control. Alternatively, select patients with low-volume, indolent metastases outside the liver (particularly within the lung) may be observed after completing liver-directed therapy.</p><p class="headingAnchor" id="H2704196650"><span class="h4">Locoregional therapies</span><span class="headingEndMark"> — </span>The liver is the most common site of disease in patients with metastatic uveal melanoma. In patients with hepatic metastases, data suggest that liver-directed therapy can improve objective response rates and is associated with longer progression-free survival (PFS) [<a href="#rid20">20-22</a>]. However, an OS benefit for liver-directed therapy has not been established. Liver-directed therapies are being compared with other locoregional and systemic treatments in randomized trials, but the optimal liver-directed therapy is not known. Selection of therapy is based on clinician and institutional expertise.</p><p>Locoregional therapies that are used to treat metastatic uveal melanoma include [<a href="#rid23">23,24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic arterial infusion of chemotherapy (HAI)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Embolization procedures</p><p class="bulletIndent2"><span class="glyph">•</span>Transarterial chemoembolization (TACE)</p><p class="bulletIndent2"><span class="glyph">•</span>Radioembolization</p><p class="bulletIndent2"><span class="glyph">•</span>Bland embolization</p><p class="bulletIndent2"><span class="glyph">•</span>Immunoembolization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated hepatic therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Percutaneous hepatic perfusion (PHP)</p><p class="bulletIndent2"><span class="glyph">•</span>Isolated hepatic perfusion (IHP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ablative therapies (eg, radiofrequency ablation, cryoablation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical resection</p><p></p><p>These techniques are described as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatic arterial infusion of chemotherapy</strong> – HAI delivers chemotherapy directly to the liver metastases via a catheter connected to the hepatic artery. Catheters can be introduced surgically via the gastroduodenal artery or percutaneously via the femoral artery [<a href="#rid23">23,24</a>]. HAI treats liver metastases by taking advantage of the dual blood supply of the liver; recruited hepatic artery branches vascularize the melanoma metastases, whereas portal circulation provides blood to the normal liver tissue.</p><p></p><p class="bulletIndent1">Fotemustine is the most common chemotherapy regimen used with HAI. Fotemustine is used in Europe, but this agent is not approved in the United States. Other regimens such as <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> [<a href="#rid25">25</a>] and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid26">26</a>] have also been used. In a randomized trial, intrahepatic artery infusion with fotemustine [<a href="#rid27">27,28</a>] improved progression-free survival (PFS) and response rates, but not OS compared with systemic chemotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fotemustine</strong> – In a phase III trial (EORTC 18021), 171 patients with uveal melanoma and metastases limited to the liver were randomly assigned to fotemustine given either intra-arterially or intravenously [<a href="#rid27">27</a>]. At a median follow-up of 1.6 years, compared with intravenous fotemustine, intra-arterial fotemustine improved PFS (median 5 versus 4 months, hazard ratio [HR] 0.62, 95% CI 0.45-0.84), and response rates (11 versus 2 percent), but not OS (median 15 versus 14 months, HR 1.09, 95% CI 0.79-1.5). Grade ≥3 toxicities due to intra-arterial fotemustine included catheter complications (12 percent), liver toxicity (5 percent), and two treatment-related deaths.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embolization procedures</strong> – The hepatic artery supplies most of the blood to the hepatic metastases, rather than the portal vein. Various embolization procedures have been developed that target the hepatic artery to eliminate the tumor’s blood supply.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transarterial chemoembolization</strong> – Transarterial liver chemoembolization (TACE) combines hepatic artery embolization with intra-arterial infusion of chemotherapy. The embolization leads to ischemia of the metastatic liver lesions as well as targeted chemotherapy to the liver lesions, which reduces the risk of systemic toxicity. In observational and phase I/II studies of patients with metastatic uveal melanoma treated with TACE (using <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid26">26,29-32</a>], fotemustine [<a href="#rid31">31,33</a>], 1,3-bis(2-chloro-ethyl)-1-nitrosourea [BCNU] [<a href="#rid34">34</a>], or drug-eluting beads loaded with <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> [DEBIRI] [<a href="#rid35">35-37</a>]), objective response rates were variable (between 6 and 57 percent), and median OS ranged between 6 and 30 months [<a href="#rid38">38</a>]. TACE is generally well-tolerated, although severe toxicities such as disseminated intravascular coagulation and cerebral infarctions have been reported [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent2">The use of TACE in other liver malignancies, such as hepatocellular carcinoma, is discussed separately. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'Technique for TACE'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Radioembolization</strong> – Radioembolization (ie, selective internal radiation therapy) uses intra-arterial injection of yttrium-90 (Y90)-labeled glass or resin microspheres to induce extensive tumor necrosis [<a href="#rid39">39-42</a>]. Radioembolization is frequently used to treat hepatic metastases from uveal melanoma.</p><p></p><p class="bulletIndent2">A randomized phase II trial (SirTac) of 40 patients with liver-dominant metastatic uveal melanoma compared radioembolization to TACE [<a href="#rid43">43</a>]. In preliminary results, at median follow-up of 14 months, best overall response rates (95 versus 85 percent) were similar for the two treatment arms. In an exploratory analysis, radioembolization improved hepatic (median 8 versus 2 months) and overall PFS (5 versus 2 months) compared with TACE.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other embolization procedures</strong> – Other embolization procedures include bland embolization and immunoembolization with granulocyte-macrophage colony-stimulating factor (GM-CSF) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated hepatic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Isolated hepatic perfusion</strong> – IHP is a one-time opens surgical procedure where the vascular supply to the liver is isolated. This approach allows delivery of high doses of chemotherapy (typically <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a>) directly to the liver metastases. IHP is not widely used since the procedure takes many hours to complete, cannot be repeated, and is associated with significant toxicity and prolonged hospital stays [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2">In a randomized, controlled phase III trial (SCANDIUM) of 93 patients with metastatic uveal melanoma and isolated liver metastases, IHP improved hepatic PFS (9 versus 3 months), overall PFS (7 versus 3 months), and overall response rates (40 versus 5 percent) compared with investigators choice of best alternative care (chemotherapy, immunotherapy, or other locoregional therapies) [<a href="#rid21">21</a>]. Follow-up of OS in this trial is still ongoing. In observational studies of patients with metastatic uveal melanoma treated with IHP, median OS was approximately 10 to 12 months [<a href="#rid45">45-50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Percutaneous hepatic perfusion</strong> – PHP is a repeatable procedure where chemotherapy is administered via percutaneous catheters directly into the liver via the hepatic artery. The venous blood from the liver is then removed from a catheter in the inferior vena cava, filtered extracorporeally to remove the chemotherapy, and then returned into circulation [<a href="#rid24">24,51-54</a>]. <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">Melphalan</a> is the most commonly used chemotherapy in PHP.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Melphalan</strong> – In a phase III trial, 93 patients with melanoma liver metastases were randomly assigned to either PHP of <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> or best alternative care. A majority (approximately 89 percent) of patients had uveal melanoma [<a href="#rid55">55</a>]. Melphalan infusion improved hepatic PFS (median 7 versus 2 months) and overall PFS (5 versus 2 months), but not OS (median 11 versus 10 months). Most treatment-related toxicities from melphalan were due to bone marrow suppression.</p><p></p><p class="bulletIndent3">PHP improved efficacy and was well tolerated in a subsequent phase III trial (FOCUS) [<a href="#rid22">22</a>]. In this study, 144 patients with ocular melanoma metastases were randomly assigned to either PHP with <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> or best alternative care (transarterial chemoembolization, <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, or <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>). In preliminary results, compared with best alternative care, PHP improved objective response rates (36 versus 13 percent) and overall PFS (median 9 versus 3 months, HR 0.38, 95% CI 0.23-0.63). OS was similar between the two treatment arms (median 19 versus 15 months, HR 0.70, 95% CI 0.43-1.13). Treatment-related toxicities for PHP included bone marrow suppression (22 percent), respiratory (6 percent), and cardiac disorders (5 percent). Of note, due to slow enrollment, the trial was amended to become a single-arm trial with all patients receiving PHP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery, radiation therapy, and ablative procedures</strong> – In patients with oligometastatic disease, local therapies include surgery [<a href="#rid24">24,56-58</a>], stereotactic radiation therapy (RT) [<a href="#rid59">59</a>], or ablative procedures such as radiofrequency ablation (RFA) and cryotherapy. Some treatments can be performed with curative intent; however candidates for local therapies are rare (approximately 2 to 7 percent of all patients) and likely to have a better prognosis due to selection bias [<a href="#rid24">24</a>]. There are no randomized trials that have compared metastasectomy or ablation with systemic therapy or best supportive care. (See  <a class="medical medical_review" href="/d/html/131562.html" rel="external">"Metastatic melanoma: Surgical management"</a>.)</p><p></p><p class="headingAnchor" id="H2828547395"><span class="h3">Significant extrahepatic disease</span></p><p class="headingAnchor" id="H663823869"><span class="h4">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with significant extrahepatic disease who are eligible for systemic therapy, we suggest the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 3</a>) rather than single-agent immunotherapy, as indirect comparisons of some studies suggest better response rates and survival outcomes for this combination. Significant extrahepatic disease is defined as tumor burden outside the liver that is extensive enough to require treatment (eg, due to symptoms, tumor bulk, and/or rapidly progressive disease).</p><p>Observational and phase II studies suggest some limited activity for this combination as initial therapy in patients with uveal melanoma, with response rates of up to 18 percent, median PFS of up to six months, and median OS of up to 19 months [<a href="#rid60">60-64</a>]. This is in contrast to the dramatic efficacy of these agents in those with advanced or metastatic cutaneous melanoma, which is discussed separately. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p>As an example, in a single-arm phase II study, 35 patients with metastatic uveal melanoma were treated with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> for four cycles followed by maintenance nivolumab [<a href="#rid65">65</a>]. At a median follow-up of 60 weeks, objective responses were seen in 6 of 33 patients (18 percent), including one complete and five partial responses; median PFS and OS were 6 and 19 months, respectively.</p><p>However, in another phase II study evaluating <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> in 52 patients with systemic therapy-naïve metastatic melanoma, median PFS and OS were 3 and 13 months, respectively [<a href="#rid64">64</a>], which is similar to the survival outcomes seen in separate studies of single-agent immunotherapy. (See <a class="local">'Single-agent immunotherapy'</a> below.)</p><p class="headingAnchor" id="H893239756"><span class="h4">Single-agent immunotherapy</span><span class="headingEndMark"> — </span>Patients who decline or are ineligible for the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> (eg, due to potential toxicity) may alternatively be offered single-agent immunotherapy with a PD-1 inhibitor [<a href="#rid60">60,66,67</a>]. Our preferred agents include nivolumab  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 4</a>) and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 5</a>). However, efficacy for single-agent immunotherapy is limited in this disease.</p><p>Patients who are unable to tolerate systemic therapy may be offered best supportive care.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong> – In a retrospective analysis, 56 patients with metastatic uveal melanoma refractory to prior therapies were treated with various PD-1 or programmed cell death ligand 1 (PD-L1) inhibitors, including approximately two-thirds with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid67">67</a>]. In the entire study population, objective responses were seen in two patients (4 percent); median PFS and OS were three and eight months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong> – In a single-arm, open-label phase II trial (CheckMate 172), the efficacy of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> was evaluated in approximately 1000 patients with advanced melanoma refractory to <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid60">60</a>]. Among the subset of 103 patients with ocular melanoma, median OS was 13 months, and 18-month OS was 35 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CTLA-4 inhibitors</strong> – In patients with immunotherapy-naïve metastatic uveal melanoma, the use of single-agent cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors is less preferred than single agent PD-1 inhibitors. While clinical trials have not directly compared the efficacy of these agents in patients with uveal melanoma, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> is generally associated with a higher risk of immune-related adverse events. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a> and  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Nivolumab plus ipilimumab (preferred)'</a>.)</p><p></p><p class="bulletIndent1">Observational and early phase II studies have demonstrated only limited efficacy for these agents (eg, <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid68">68-71</a>] and <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> [<a href="#rid72">72</a>]), with objective response rates of up to 8 percent, median PFS of up to seven months, and OS of up to 10 months. Additionally, patients with uveal melanoma were excluded from the phase III trial that established a survival benefit of ipilimumab in those with metastatic cutaneous melanoma [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Ipilimumab'</a>.)</p><p></p><p class="headingAnchor" id="H3043227280"><span class="h3">Brain metastases</span><span class="headingEndMark"> — </span>The management of brain metastases in patients with melanoma is complex and may also involve other treatment strategies. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/7611.html" rel="external">"Management of brain metastases in melanoma"</a>.)</p><p class="headingAnchor" id="H802732688"><span class="h2">Options not typically used</span></p><p class="headingAnchor" id="H4136191770"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>We do not typically use chemotherapy in patients with metastatic uveal melanoma. No chemotherapeutic agent, alone or in combination, has been found to extend OS in patients with metastatic disease, with response rates generally under 10 percent. Agents studied have included <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, <a class="drug drug_general" data-topicid="134625" href="/d/drug information/134625.html" rel="external">treosulfan</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, fotemustine-based regimens, and others [<a href="#rid27">27,44,74-80</a>].</p><p>In an analysis of 64 patients treated for metastatic uveal melanoma with a variety of regimens that included <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a>, only one complete response and five partial responses were observed (9 percent) [<a href="#rid77">77</a>]. Only two responses were seen in the 56 patients with hepatic metastases. Other studies have not resulted in consistently higher response rates [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/d/html/15406.html" rel="external">"Cytotoxic chemotherapy for metastatic melanoma"</a>.)</p><p class="headingAnchor" id="H972015152"><span class="h3">Molecularly targeted agents</span><span class="headingEndMark"> — </span>BRAF plus MEK inhibitors (<a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>) are approved for patients with any treatment-refractory solid tumor that has a <em>BRAF </em>V600E mutation. However, these agents are not used in metastatic uveal melanoma which rarely harbor <em>BRAF</em> mutations [<a href="#rid81">81</a>]. The use of BRAF plus MEK inhibitors in other types of metastatic melanoma is discussed separately. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Dabrafenib plus trametinib'</a>.)</p><p>Additionally, we do not use MEK inhibitors to treat metastatic uveal melanoma, which has a different molecular pathogenesis than cutaneous melanoma. Data also suggest limited activity for MEK inhibitors, including several randomized trials of <a class="drug drug_general" data-topicid="127843" href="/d/drug information/127843.html" rel="external">selumetinib</a> as a single agent or in combination with chemotherapy [<a href="#rid74">74,80,82,83</a>]. (See  <a class="medical medical_review" href="/d/html/16540.html" rel="external">"The molecular biology of melanoma", section on 'Uveal melanomas'</a>.)</p><p class="headingAnchor" id="H349223898"><span class="h2">Experimental agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alrizomadlin</strong> – Alrizomadlin, a novel inhibitor of MDM2-p53, demonstrated objective response rates of 24 percent patients with metastatic melanoma who progressed on prior immunotherapy, in preliminary results from one phase II trial [<a href="#rid84">84</a>]. Among the eight patients with uveal melanoma, the objective response and disease control rates were 14 and 72 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous tumor-infiltrating lymphocytes</strong> – Preliminary evidence from a phase II study indicated that autologous tumor-infiltrating lymphocytes could mediate regression of metastatic uveal melanoma [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epigenetic therapies</strong> – Given that uveal melanoma is a genetically simple disease characterized by few somatic variants compared with cutaneous melanoma, other factors, such as epigenetic alterations, may be important in the pathogenesis of uveal melanoma. Preclinical data suggest efficacy for histone deacetylase (HDAC) inhibitors [<a href="#rid86">86,87</a>] and bromodomain and extra-terminal domain (BET) protein inhibitors [<a href="#rid88">88</a>]. These treatments are in clinical development for uveal melanoma.</p><p></p><p class="headingAnchor" id="H3379022821"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>A majority of patients diagnosed with uveal melanoma experience long-term survival, with an estimated thirty-year survival rate of 67 percent [<a href="#rid89">89</a>]. However, the prognosis has historically been poor for those with metastatic disease. Further studies are necessary to determine if long-term survival will improve in the contemporary era of targeted therapy.</p><p>Prior to the approval of <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a>, the median overall survival (OS) for patients with metastatic disease was approximately six to twelve months [<a href="#rid4">4,20,89-91</a>]. In contrast, tebentafusp increased the median OS to approximately two years in a phase III trial [<a href="#rid11">11</a>]. (See <a class="local">'Tebentafusp'</a> above.)</p><p>A retrospective review of 89 patients found the development of extrahepatic only metastases, Eastern Cooperative Oncology Group performance status of 0, receipt of immunotherapy, and female sex to be associated with improved survival [<a href="#rid92">92</a>]. Prognostic factors associated with decreased survival included male sex, elevated lactate dehydrogenase (LDH), elevated alkaline phosphatase, and increased diameter of the largest liver metastasis (≥3 cm) [<a href="#rid20">20</a>]. The extent of metastatic disease is incorporated into the AJCC Tumor, Node, Metastasis (TNM) staging system  (<a class="graphic graphic_table graphicRef110766" href="/d/graphic/110766.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef110765" href="/d/graphic/110765.html" rel="external">table 1</a>), with increasing stage associated with lower OS  (<a class="graphic graphic_figure graphicRef112190" href="/d/graphic/112190.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H4218837238"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H2264399311"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Most patients with metastatic uveal melanoma develop recurrent disease after receiving treatment to the primary eye lesion. Patients who present with a primary uveal melanoma and synchronous metastases are rare. (See <a class="local">'Timing of metastases'</a> above.)</p><p></p><p class="bulletIndent1">The most common sites include the liver, followed by the lung, bones, and skin/subcutaneous tissue. Lymph node and brain metastases are rare. (See <a class="local">'Sites of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnosis should be suspected in patients with a known history of primary uveal melanoma and systemic metastases (such as predominant disease burden in the liver). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unknown primary</strong> – Patients with <em>de novo</em> metastatic melanoma (especially those with hepatic metastases) and an unknown primary site should be referred to ophthalmology to assess for a primary eye lesion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging studies</strong> – We obtain MRI of the liver with <a class="drug drug_general" data-topicid="9085" href="/d/drug information/9085.html" rel="external">gadoxetate</a> (Eovist) contrast to assess for hepatic metastases. We also obtain contrast-enhanced CT of the chest to assess for extrahepatic sites of disease. Patients may be offered the option of MRI of the brain with contrast to assess for CNS metastases. (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biopsy</strong> – The diagnosis of metastatic uveal melanoma is confirmed on biopsy and histopathologic evaluation of distant metastatic lesions. (See <a class="local">'Diagnostic biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype assessment prior to systemic therapy</strong> – Prior to initiating systemic therapy in all patients with metastatic uveal melanoma, we obtain a genotyping assay for the presence of human leukocyte antigen (HLA)-A*02:01  (<a class="graphic graphic_algorithm graphicRef139783" href="/d/graphic/139783.html" rel="external">algorithm 1</a>). (See <a class="local">'Genotype assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a positive HLA-A*02:01</strong> <strong>genotype</strong> – For patients with treatment-naïve metastatic disease who are HLA-A*02:01 positive, we recommend <a class="drug drug_general" data-topicid="134894" href="/d/drug information/134894.html" rel="external">tebentafusp</a>  (<a class="graphic graphic_figure graphicRef135190" href="/d/graphic/135190.html" rel="external">figure 2</a>) rather than other systemic agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>), as this approach improved overall survival (OS) in a phase III trial. (See <a class="local">'HLA-A*02:01 positive'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a negative HLA-A*02:01 genotype</strong> – For patients with treatment-naïve metastatic disease who are not HLA-A*02:01-positive or those with bulky or rapidly progressive disease, we offer enrollment in formal clinical trials whenever possible (see <a class="local">'HLA-A*02:01 negative'</a> above and <a class="local">'Experimental agents'</a> above):</p><p></p><p class="bulletIndent1">For patients who are ineligible for or decline clinical trials, our initial treatment approach is based upon the predominant location of metastatic disease  (<a class="graphic graphic_algorithm graphicRef139783" href="/d/graphic/139783.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver-dominant disease</strong> – For patients with liver-dominant disease, we suggest locoregional therapies rather than systemic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). However, initial systemic therapy is an appropriate alternative, given the poor prognosis of this disease and limited randomized trials comparing locoregional and systemic therapies. (See <a class="local">'Liver-dominant disease'</a> above.)</p><p></p><p class="bulletIndent2">Examples of locoregional treatments include liver-directed therapy for hepatic metastases (hepatic arterial infusion of chemotherapy; embolization procedures; isolated hepatic therapy), surgery, radiation therapy (RT), and ablative therapies. (See <a class="local">'Locoregional therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Significant extrahepatic disease</strong> – For patients with significant extrahepatic disease who are eligible for systemic therapy, we suggest initial treatment with the combination of <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef130970" href="/d/graphic/130970.html" rel="external">table 3</a>) rather than single-agent immunotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Significant extrahepatic disease is defined as tumor burden outside the liver that is extensive enough to require treatment (eg, due to symptoms, tumor bulk, and/or rapidly progressive disease). (See <a class="local">'Significant extrahepatic disease'</a> above and <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent2">Patients who decline or are ineligible for combination immunotherapy (eg, due to potential toxicity) may alternatively be offered single-agent immunotherapy with PD-1 inhibitors (eg, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/d/graphic/127100.html" rel="external">table 4</a>), <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/d/graphic/127101.html" rel="external">table 5</a>)). (See <a class="local">'Single-agent immunotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis has historically been poor for patients with metastatic uveal melanoma. Further studies are necessary to determine if long-term survival will improve in the contemporary era of targeted therapy. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998; 83:1664.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol 2017; 101:38.</a></li><li><a class="nounderline abstract_t">Awh CC, Wilson MW. Symptomatic Liver Metastasis Prompting Diagnosis of Uveal Melanoma. Ocul Oncol Pathol 2020; 6:164.</a></li><li><a class="nounderline abstract_t">Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44:4651.</a></li><li><a class="nounderline abstract_t">Kolandjian NA, Wei C, Patel SP, et al. Delayed systemic recurrence of uveal melanoma. Am J Clin Oncol 2013; 36:443.</a></li><li><a class="nounderline abstract_t">Eskelin S, Pyrhönen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology 2000; 107:1443.</a></li><li><a class="nounderline abstract_t">Collaborative Ocular Melanoma Study Group.. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670.</a></li><li><a class="nounderline abstract_t">Finger PT, Kurli M, Reddy S, et al. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005; 89:1270.</a></li><li><a class="nounderline abstract_t">Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, et al. Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol 2013; 6:1230.</a></li><li><a class="nounderline abstract_t">Wei AZ, Uriel M, Porcu A, et al. Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Front Oncol 2022; 12:961517.</a></li><li><a class="nounderline abstract_t">Nathan P, Hassel JC, Rutkowski P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2021; 385:1196.</a></li><li class="breakAll">BR220737 - SeCore CDx HLA Sequencing System. US Food and Drug Administration. Available at: https://www.fda.gov/vaccines-blood-biologics/substantially-equivalent-510k-device-information/br220737-secore-cdx-hla-sequencing-system (Accessed on December 05, 2022).</li><li class="breakAll">Tebentafusp: US Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s002lbl.pdf (Accessed on December 05, 2022).</li><li><a class="nounderline abstract_t">Sato T, Nathan PD, Hernandez-Aya LF, et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma. J Clin Oncol 2017; 35S:ASCO #9531.</a></li><li><a class="nounderline abstract_t">Middleton MR, McAlpine C, Woodcock VK, et al. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin Cancer Res 2020; 26:5869.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Nathan P, Sacco JJ, et al. Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol 2022; 40:1939.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Butler MO, Shoushtari AN, et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 2022; 28:2364.</a></li><li><a class="nounderline abstract_t">Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 2023; 389:2256.</a></li><li class="breakAll">European Medicines Agency: An official website of the European Union. https://www.ema.europa.eu/en (Accessed on August 24, 2022).</li><li><a class="nounderline abstract_t">Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30:1370.</a></li><li><a class="nounderline abstract_t">Olofsson Bagge R, Nelson A, Shafazand A, et al. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol 2023; 41:3042.</a></li><li><a class="nounderline abstract_t">Zagar JS, Orloff MM, Ferrucci PF, et al. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). J Clin Oncol 2022; 40;16S.</a></li><li><a class="nounderline abstract_t">Rodriguez-Vidal C, Fernandez-Diaz D, Fernandez-Marta B, et al. Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Agarwala SS, Eggermont AM, O'Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 2014; 120:781.</a></li><li><a class="nounderline abstract_t">Boone BA, Perkins S, Bandi R, et al. Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. J Surg Oncol 2018; 117:940.</a></li><li><a class="nounderline abstract_t">Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004; 14:217.</a></li><li><a class="nounderline abstract_t">Leyvraz S, Piperno-Neumann S, Suciu S, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol 2014; 25:742.</a></li><li><a class="nounderline abstract_t">Siegel R, Hauschild A, Kettelhack C, et al. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 2007; 33:627.</a></li><li><a class="nounderline abstract_t">Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74:e38.</a></li><li><a class="nounderline abstract_t">Shibayama Y, Namikawa K, Sone M, et al. Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population. Int J Clin Oncol 2017; 22:577.</a></li><li><a class="nounderline abstract_t">Schuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20:191.</a></li><li><a class="nounderline abstract_t">Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974.</a></li><li><a class="nounderline abstract_t">Edelhauser G, Schicher N, Berzaczy D, et al. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. AJR Am J Roentgenol 2012; 199:1387.</a></li><li><a class="nounderline abstract_t">Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15:297.</a></li><li><a class="nounderline abstract_t">Carling U, Dorenberg EJ, Haugvik SP, et al. Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications. Cardiovasc Intervent Radiol 2015; 38:1532.</a></li><li><a class="nounderline abstract_t">Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23:131.</a></li><li><a class="nounderline abstract_t">Valpione S, Aliberti C, Parrozzani R, et al. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Res 2015; 25:164.</a></li><li><a class="nounderline abstract_t">Gupta S, Bedikian AY, Ahrar J, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol 2010; 33:474.</a></li><li><a class="nounderline abstract_t">Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013; 36:158.</a></li><li><a class="nounderline abstract_t">Gonsalves CF, Eschelman DJ, Adamo RD, et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology 2019; 293:223.</a></li><li><a class="nounderline abstract_t">Levey AO, Elsayed M, Lawson DH, et al. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. Cardiovasc Intervent Radiol 2020; 43:254.</a></li><li><a class="nounderline abstract_t">Arulananda S, Parakh S, Palmer J, et al. A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. Cancer Rep (Hoboken) 2019; 2:e1183.</a></li><li><a class="nounderline abstract_t">Anna Peuker CA, De Bucourt M, Gebauer B, et al. First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma. J Clin Oncol 2022; 40;16S.</a></li><li><a class="nounderline abstract_t">Valsecchi ME, Terai M, Eschelman DJ, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases. J Vasc Interv Radiol 2015; 26:523.</a></li><li><a class="nounderline abstract_t">Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6:3062.</a></li><li><a class="nounderline abstract_t">Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9:6343.</a></li><li><a class="nounderline abstract_t">van Iersel LB, Hoekman EJ, Gelderblom H, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol 2008; 15:1891.</a></li><li><a class="nounderline abstract_t">Ben-Shabat I, Belgrano V, Ny L, et al. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol 2016; 23:1327.</a></li><li><a class="nounderline abstract_t">de Leede EM, Burgmans MC, Kapiteijn E, et al. Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres. Melanoma Res 2016; 26:588.</a></li><li><a class="nounderline abstract_t">van Iersel LB, de Leede EM, Vahrmeijer AL, et al. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study. Eur J Surg Oncol 2014; 40:1557.</a></li><li><a class="nounderline abstract_t">Artzner C, Mossakowski O, Hefferman G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging 2019; 19:31.</a></li><li><a class="nounderline abstract_t">Karydis I, Gangi A, Wheater MJ, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol 2018; 117:1170.</a></li><li><a class="nounderline abstract_t">Forster MR, Rashid OM, Perez MC, et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 2014; 109:434.</a></li><li><a class="nounderline abstract_t">Vogl TJ, Koch SA, Lotz G, et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol 2017; 40:864.</a></li><li><a class="nounderline abstract_t">Hughes MS, Zager J, Faries M, et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann Surg Oncol 2016; 23:1309.</a></li><li><a class="nounderline abstract_t">Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93:1042.</a></li><li><a class="nounderline abstract_t">Akyuz M, Yazici P, Dural C, et al. Laparoscopic management of liver metastases from uveal melanoma. Surg Endosc 2016; 30:2567.</a></li><li><a class="nounderline abstract_t">Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 2004; 100:122.</a></li><li><a class="nounderline abstract_t">Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 2011; 18:1081.</a></li><li><a class="nounderline abstract_t">Nathan P, Ascierto PA, Haanen J, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 2019; 119:168.</a></li><li><a class="nounderline abstract_t">Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer 2020; 8.</a></li><li><a class="nounderline abstract_t">Heppt MV, Amaral T, Kähler KC, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer 2019; 7:299.</a></li><li><a class="nounderline abstract_t">Rapisuwon S, Izar B, Batenchuk C, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer 2019; 7:61.</a></li><li><a class="nounderline abstract_t">Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol 2021; 39:586.</a></li><li><a class="nounderline abstract_t">Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol 2021; 39:599.</a></li><li><a class="nounderline abstract_t">Kottschade LA, McWilliams RR, Markovic SN, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res 2016; 26:300.</a></li><li><a class="nounderline abstract_t">Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016; 122:3344.</a></li><li><a class="nounderline abstract_t">Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013; 119:3687.</a></li><li><a class="nounderline abstract_t">Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911.</a></li><li><a class="nounderline abstract_t">Piulats Rodriguez JM, Ochoa de Olza M, Codes M, et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial. J Clin Oncol 2014; 32S:ASCO #9033.</a></li><li><a class="nounderline abstract_t">Zimmer L, Vaubel J, Mohr P, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. PLoS One 2015; 10:e0118564.</a></li><li><a class="nounderline abstract_t">Joshua AM, Monzon JG, Mihalcioiu C, et al. A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res 2015; 25:342.</a></li><li><a class="nounderline abstract_t">Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014; 311:2397.</a></li><li><a class="nounderline abstract_t">Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17:1826.</a></li><li><a class="nounderline abstract_t">Sacco JJ, Nathan PD, Danson S, et al. Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. J Clin Oncol 2013; 31S:ASCO #9031.</a></li><li><a class="nounderline abstract_t">Flaherty LE, Unger JM, Liu PY, et al. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568.</a></li><li><a class="nounderline abstract_t">Nathan FE, Berd D, Sato T, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201.</a></li><li><a class="nounderline abstract_t">Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39:1115.</a></li><li><a class="nounderline abstract_t">Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). J Clin Oncol 2018; 36:1232.</a></li><li><a class="nounderline abstract_t">Pópulo H, Soares P, Rocha AS, et al. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res 2010; 20:107.</a></li><li><a class="nounderline abstract_t">Nathan P, Needham A, Corrie PG, et al. SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Ann Oncol 2019; 30;5S.</a></li><li><a class="nounderline abstract_t">Steeb T, Wessely A, Ruzicka T, et al. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer 2018; 103:41.</a></li><li><a class="nounderline abstract_t">Tolcher AW, Reeves JA, McKean M, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. J Clin Oncol 2021; 39;15S.</a></li><li><a class="nounderline abstract_t">Chandran SS, Somerville RP, Yang JC, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol 2017.</a></li><li><a class="nounderline abstract_t">Matatall KA, Agapova OA, Onken MD, et al. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 2013; 13:371.</a></li><li><a class="nounderline abstract_t">Landreville S, Agapova OA, Matatall KA, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012; 18:408.</a></li><li><a class="nounderline abstract_t">Ambrosini G, Sawle AD, Musi E, Schwartz GK. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells. Oncotarget 2015; 6:33397.</a></li><li><a class="nounderline abstract_t">Stålhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. Commun Med (Lond) 2022; 2:18.</a></li><li><a class="nounderline abstract_t">Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881.</a></li><li><a class="nounderline abstract_t">Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res 2019; 29:561.</a></li><li><a class="nounderline abstract_t">Demkowicz P, Pointdujour-Lim R, Miguez S, et al. Determinants of overall survival in patients with metastatic uveal melanoma. Cancer 2023; 129:3275.</a></li></ol></div><div id="topicVersionRevision">Topic 113047 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781962" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574175" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Metastatic disease from uveal melanoma: treatment options and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32509760" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Symptomatic Liver Metastasis Prompting Diagnosis of Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578381" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Very long-term prognosis of patients with malignant uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22706174" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Delayed systemic recurrence of uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10919885" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11346394" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170114" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Whole body PET/CT for initial staging of choroidal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23826405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ocular melanoma: an overview of the current status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36212499" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551229" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551229" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551229" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32816891" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35254876" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36229663" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870955" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870955" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31150059" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36940407" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32911759" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment of Metastatic Uveal Melanoma: Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24301420" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29878390" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15179192" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24510314" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17196362" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19467811" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Transarterial chemoembolization of liver metastases in patients with uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144882" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20335820" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3398202" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169735" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034309" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832764" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368137" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25521594" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935383" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22526099" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31453767" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31686137" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32721131" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25678394" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955785" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695133" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18470571" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26628434" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513071" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125340" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31146793" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29284076" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24249545" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28144756" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597368" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19429579" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term survival of uveal melanoma patients after surgery for liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26310535" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Laparoscopic management of liver metastases from uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692032" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prolonged survival after complete resection of metastases from intraocular melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21046264" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31445199" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32581057" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31722735" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30832716" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417511" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33125309" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848796" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The use of pembrolizumab for the treatment of metastatic uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27533448" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23913718" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24067719" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25761109" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26050146" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A phase 2 study of tremelimumab in patients with advanced uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21639810" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24938562" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971664" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856657" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261748" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12736111" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29528792" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173664" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30205280" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28395880" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23915344" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22038994" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26397223" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35603296" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704381" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Uveal melanoma: trends in incidence, treatment, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30664106" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37382208" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Determinants of overall survival in patients with metastatic uveal melanoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
